{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T19:21:03Z","timestamp":1768159263301,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40261-019-00811-7","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T13:02:43Z","timestamp":1561986163000},"page":"825-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Maria Carmela","family":"Annunziata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"issue":"16","key":"811_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","volume":"33","author":"MG Fakih","year":"2015","unstructured":"Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33(16):1809\u201324.","journal-title":"J Clin Oncol."},{"issue":"1","key":"811_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570163812666150602144310","volume":"12","author":"TA Baudino","year":"2015","unstructured":"Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3\u201320.","journal-title":"Curr Drug Discov Technol."},{"issue":"4","key":"811_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-018-0653-5","volume":"40","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Taborelli M, Francescon S, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm. 2018;40(4):795\u2013802.","journal-title":"Int J Clin Pharm."},{"key":"811_CR4","first-page":"650482","volume":"2011","author":"G Fabbrocini","year":"2011","unstructured":"Fabbrocini G, Romano MC, Cameli N, et al. \u201cIl corpo ritrovato\u201d: dermocosmetological skin care project for the oncologic patient. ISRN Oncol. 2011;2011:650482.","journal-title":"ISRN Oncol."},{"issue":"2","key":"811_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","volume":"16","author":"C Pinto","year":"2011","unstructured":"Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16(2):228\u201338.","journal-title":"Oncologist."},{"key":"811_CR6","doi-asserted-by":"crossref","unstructured":"Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3-8.","DOI":"10.1016\/S0959-8049(01)00230-1"},{"issue":"4","key":"811_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","volume":"33","author":"J Mendelsohn","year":"2006","unstructured":"Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369\u201385.","journal-title":"Semin Oncol."},{"issue":"9","key":"811_CR8","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1432-0436.2007.00238.x","volume":"75","author":"M Sibilia","year":"2007","unstructured":"Sibilia M, Kroismayr R, Lichtenberger BM, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007;75(9):770\u201387.","journal-title":"Differentiation."},{"issue":"8","key":"811_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351\u20137.","journal-title":"J Clin Oncol."},{"key":"811_CR10","unstructured":"European Medicines Agency. Erbitux 5\u00a0mg\/mL solution for infusion [summary of product characteristics]. 2017. \n                    http:\/\/www.ema.europa.eu\/documents\/product-information\/erbitux-epar-product-information_en.pdf\n                    \n                  . Accessed 26 Nov 2018."},{"key":"811_CR11","unstructured":"European Medicines Agency. Vectibix 20\u00a0mg\/mL concentrate for solution for infusion [summary of product characteristics]. 2018. \n                    http:\/\/www.ema.europa.eu\/documents\/product-information\/vectibix-epar-product-information_en.pdf\n                    \n                  . Accessed 26 Nov 2018."},{"issue":"7","key":"811_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","volume":"22","author":"C Bokemeyer","year":"2011","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535\u201346.","journal-title":"Ann Oncol."},{"issue":"11","key":"811_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023\u201334.","journal-title":"N Engl J Med."},{"issue":"31","key":"811_CR14","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697\u2013705.","journal-title":"J Clin Oncol."},{"issue":"31","key":"811_CR15","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706\u201313.","journal-title":"J Clin Oncol."},{"issue":"14","key":"811_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408\u201317.","journal-title":"N Engl J Med."},{"issue":"7","key":"811_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692\u2013700.","journal-title":"J Clin Oncol."},{"issue":"1","key":"811_CR18","doi-asserted-by":"publisher","first-page":"e000147","DOI":"10.1136\/esmoopen-2016-000147","volume":"2","author":"L Salvatore","year":"2017","unstructured":"Salvatore L, Aprile G, Arnoldi E, et al. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open. 2017;2(1):e000147.","journal-title":"ESMO Open."},{"issue":"8","key":"811_CR19","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol."},{"issue":"4","key":"811_CR20","doi-asserted-by":"publisher","first-page":"e1004969","DOI":"10.1080\/23723556.2015.1004969","volume":"2","author":"M Holcmann","year":"2015","unstructured":"Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4):e1004969.","journal-title":"Mol Cell Oncol."},{"issue":"2","key":"811_CR21","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.3747\/co.v18i2.605","volume":"18","author":"N Mittmann","year":"2011","unstructured":"Mittmann N, Seung SJ. Rash rates with EGFR inhibitors: meta-analysis. Curr Oncol. 2011;18(2):e54\u201363.","journal-title":"Curr Oncol."},{"issue":"Suppl 1","key":"811_CR22","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","volume":"7","author":"B Burtness","year":"2009","unstructured":"Burtness B, Anadkat M, Basti S, et al. NCCN task force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Netw. 2009;7(Suppl 1):S5\u201321 (Quiz S2\u20134).","journal-title":"J Natl Compr Cancer Netw"},{"issue":"16","key":"811_CR23","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1002\/cncr.25090","volume":"116","author":"SS Joshi","year":"2010","unstructured":"Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010;116(16):3916\u201323.","journal-title":"Cancer."},{"issue":"8","key":"811_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079\u201395.","journal-title":"Support Care Cancer."},{"issue":"4","key":"811_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"AC Rosen","year":"2013","unstructured":"Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327\u201333.","journal-title":"Am J Clin Dermatol."},{"issue":"11 Suppl 5","key":"811_CR26","first-page":"34","volume":"21","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology. 2007;21(11 Suppl 5):34\u20136.","journal-title":"Oncology."},{"issue":"24","key":"811_CR27","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2217\/fon-2018-0187","volume":"14","author":"J Beech","year":"2018","unstructured":"Beech J, Germetaki T, Judge M, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018;14(24):2531\u201341.","journal-title":"Future Oncol."},{"issue":"12","key":"811_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","volume":"21","author":"RD Hofheinz","year":"2016","unstructured":"Hofheinz RD, Deplanque G, Komatsu Y, et al. Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist. 2016;21(12):1483\u201391.","journal-title":"Oncologist."},{"issue":"4","key":"811_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jjco\/hyv207","volume":"46","author":"T Kozuki","year":"2016","unstructured":"Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291\u20138.","journal-title":"Jpn J Clin Oncol."},{"issue":"2","key":"811_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clcc.2017.12.004","volume":"17","author":"ME Lacouture","year":"2018","unstructured":"Lacouture ME, Anadkat M, Jatoi A, et al. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018;17(2):85\u201396.","journal-title":"Clin Colorectal Cancer."},{"issue":"1","key":"811_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371821","volume":"1","author":"G Fabbrocini","year":"2015","unstructured":"Fabbrocini G, Panariello L, Caro G, et al. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Skin Appendage Disord. 2015;1(1):31\u20137.","journal-title":"Skin Appendage Disord."},{"issue":"9","key":"811_CR32","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1007\/s00520-016-3231-1","volume":"24","author":"RL Braden","year":"2016","unstructured":"Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer. 2016;24(9):3943\u201350.","journal-title":"Support Care Cancer."},{"issue":"1","key":"811_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnci\/djp439","volume":"102","author":"RE Eilers Jr","year":"2010","unstructured":"Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102(1):47\u201353.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"811_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ced.12675","volume":"41","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Tournier E, Roche H, et al. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity. Clin Exp Dermatol. 2016;41(1):34\u20137.","journal-title":"Clin Exp Dermatol."},{"issue":"7","key":"811_CR35","first-page":"505","volume":"10","author":"M Jost","year":"2000","unstructured":"Jost M, Kari C, Rodeck U. The EGF receptor\u2014an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10(7):505\u201310.","journal-title":"Eur J Dermatol."},{"issue":"10","key":"811_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803\u201312.","journal-title":"Nat Rev Cancer."},{"issue":"199","key":"811_CR37","doi-asserted-by":"publisher","first-page":"199ra11","DOI":"10.1126\/scitranslmed.3005886","volume":"5","author":"BM Lichtenberger","year":"2013","unstructured":"Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5(199):199ra11.","journal-title":"Sci Transl Med."},{"issue":"5","key":"811_CR38","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","volume":"12","author":"TJ Lynch Jr","year":"2007","unstructured":"Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12(5):610\u201321.","journal-title":"Oncologist."},{"issue":"10","key":"811_CR39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","volume":"19","author":"A Jatoi","year":"2011","unstructured":"Jatoi A, Dakhil SR, Sloan JA, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer. 2011;19(10):1601\u20137.","journal-title":"Support Care Cancer."},{"issue":"4","key":"811_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"113","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847\u201353.","journal-title":"Cancer."},{"issue":"4","key":"811_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol. 2015;11(4):617\u201327.","journal-title":"Future Oncol."},{"issue":"2","key":"811_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2478\/raon-2013-0014","volume":"47","author":"J Ocvirk","year":"2013","unstructured":"Ocvirk J, Heeger S, McCloud P, et al. A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. Radiol Oncol. 2013;47(2):166\u201375.","journal-title":"Radiol Oncol."},{"issue":"6","key":"811_CR43","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/bjd.14756","volume":"175","author":"F Petrelli","year":"2016","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1166\u201374.","journal-title":"Br J Dermatol."},{"issue":"34","key":"811_CR44","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390\u20136.","journal-title":"J Clin Oncol."},{"issue":"11","key":"811_CR45","first-page":"6175","volume":"35","author":"M Yamada","year":"2015","unstructured":"Yamada M, Iihara H, Fujii H, et al. Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients. Anticancer Res. 2015;35(11):6175\u201381.","journal-title":"Anticancer Res."},{"key":"811_CR46","volume-title":"Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. New York: Wiley; 2014."},{"issue":"2","key":"811_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"AN Sapadin","year":"2006","unstructured":"Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258\u201365.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"811_CR48","first-page":"443","volume":"35","author":"YH Thong","year":"1979","unstructured":"Thong YH, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol. 1979;35(3):443\u20136.","journal-title":"Clin Exp Immunol."},{"key":"811_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.critrevonc.2017.03.032","volume":"114","author":"RD Hofheinz","year":"2017","unstructured":"Hofheinz RD, Segaert S, Safont MJ, et al. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit Rev Oncol Hematol. 2017;114:102\u201313.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"10","key":"811_CR50","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s11136-016-1288-4","volume":"25","author":"R Koukakis","year":"2016","unstructured":"Koukakis R, Gatta F, Hechmati G, et al. Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials. Qual Life Res. 2016;25(10):2645\u201356.","journal-title":"Qual Life Res."},{"issue":"2","key":"811_CR51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2012.08.023","volume":"49","author":"I L\u00e1ng","year":"2013","unstructured":"L\u00e1ng I, K\u00f6hne CH, Folprecht G, et al. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer. 2013;49(2):439\u201348.","journal-title":"Eur J Cancer."},{"issue":"2","key":"811_CR52","doi-asserted-by":"publisher","first-page":"e000041","DOI":"10.1136\/esmoopen-2016-000041","volume":"1","author":"S Siena","year":"2016","unstructured":"Siena S, Tabernero J, Bodoky G, et al. Quality of life during first-line FOLFOX4\u00b1panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open. 2016;1(2):e000041.","journal-title":"ESMO Open."},{"issue":"1","key":"811_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2340\/00015555-0174","volume":"87","author":"FS Larsen","year":"2007","unstructured":"Larsen FS, Simonsen L, Melgaard A, et al. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol. 2007;87(1):62\u20138.","journal-title":"Acta Derm Venereol."},{"issue":"1","key":"811_CR54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1684\/ejd.2010.0833","volume":"20","author":"H Sch\u00f6fer","year":"2010","unstructured":"Sch\u00f6fer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20(1):6\u201315.","journal-title":"Eur J Dermatol."},{"issue":"3","key":"811_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4155\/tde-2017-0070","volume":"9","author":"S Molesini","year":"2018","unstructured":"Molesini S, Urto F, Cvetkovska AD, et al. Influences of the vehicle in the spreading and release of betamethasone. Ther Deliv. 2018;9(3):177\u201384.","journal-title":"Ther Deliv."},{"issue":"Suppl 216","key":"811_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2340\/00015555-0387","volume":"88","author":"BH Long","year":"2008","unstructured":"Long BH. Fusidic acid in skin and soft-tissue infections. Acta Derm Venereol. 2008;88(Suppl 216):14\u201320.","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"811_CR57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2310\/7750.2006.00064","volume":"10","author":"RP Rennie","year":"2006","unstructured":"Rennie RP. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J Cutan Med Surg. 2006;10(6):277\u201380.","journal-title":"J Cutan Med Surg."},{"issue":"2","key":"811_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5694\/j.1326-5377.1996.tb101350.x","volume":"164","author":"JD Turnidge","year":"1996","unstructured":"Turnidge JD, Nimmo GR, Francis G. Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR). Med J Aust. 1996;164(2):68\u201371.","journal-title":"Med J Aust."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00811-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T23:07:16Z","timestamp":1593472036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00811-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00811-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"1 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Alfonso De Stefano received an honorarium for participation in advisory boards from Amgen. Gabriella Fabbrocini received a grant and support for travel to meetings regarding the study from LEO Pharma. Maria Carmela Annunziata, Silvana Leo, Paolo Marchetti, Maria Concetta Romano, and Ivana Romano declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The editorial assistance for the preparation of this review was unconditionally funded by LEO Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The patients whose cases are briefly reported in this review have been treated in the setting of daily clinical practice, and not as part of a clinical study of any kind. They represent a retrospective analysis and, according to Italian law, no approval from an ethics committee or institutional review board is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients\u2019 photographs were acquired during treatment according to the standard procedures of the treating dermatology unit; the patients gave their consent at the time for both the treatment and scientific diffusion of the data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}